Literature DB >> 19361301

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Roger J M Brüggemann1, Jan-Willem C Alffenaar, Nicole M A Blijlevens, Eliane M Billaud, Jos G W Kosterink, Paul E Verweij, David M Burger.   

Abstract

There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361301     DOI: 10.1086/598327

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  88 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Authors:  Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh
Journal:  Mycoses       Date:  2011-11-29       Impact factor: 4.377

3.  Long-term voriconazole and skin cancer: is there cause for concern?

Authors:  Cornelius J Clancy; M Hong Nguyen
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

4.  Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Authors:  Hans-Peter Lipp
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

5.  Increasing the dose of voriconazole compensates for enzyme induction by phenytoin.

Authors:  Isabel Spriet; Philippe Meersseman; Wouter Meersseman; Jan de Hoon; Ludo Willems
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

6.  Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.

Authors:  Eline W Muilwijk; Bart G J Dekkers; Stefanie S V Henriet; Paul E Verweij; Bregje Witjes; Astrid M L Oude Lashof; Geert H Groeneveld; Johannes van der Hoeven; Jan Willem C Alffenaar; Frans G M Russel; Frank van de Veerdonk; Roger J M Brüggemann
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

7.  Preclinical Evaluation of Acylhydrazone SB-AF-1002 as a Novel Broad-Spectrum Antifungal Agent.

Authors:  Cristina Lazzarini; Krupanandan Haranahalli; J Brian McCarthy; John Mallamo; Iwao Ojima; Maurizio Del Poeta
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

8.  SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents.

Authors:  Krupanandan Haranahalli; Cristina Lazzarini; Yi Sun; Julia Zambito; Senuri Pathiranage; J Brian McCarthy; John Mallamo; Maurizio Del Poeta; Iwao Ojima
Journal:  J Med Chem       Date:  2019-08-16       Impact factor: 7.446

Review 9.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

Review 10.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.